Biocon Biologics Secures Market Entry Date For Yesafili, An Interchangeable Biosimilar To Eylea, In The U.S.
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable* …